Venous thromboembolism (VTE) is a life-threatening complication, specially in case of recurrence. The appropriate duration of anticoagulant treatment following the first event is crucial. Risk factors that increase the risk of recurrence of VTE are many, and include medications, kidney disease, renal transplantation (RT), and a diagnosis of sickle cell disease (SCD). There are currently no guidelines that define the duration of anticoagulant therapy after the first event in a patient with RT. We report a case of recurring episodes of VTE after RT in a SCD patient. Our case suggests that the use of a long-term anticoagulant treatment may be recommended in patients with SCD and RT after the first event of VTE.
Di Maggio, R., Giuliano, A., Renda, D., Calvaruso, G., Raso, S., Pitrolo, L., et al. (2022). A Patient with Sickle Cell Disease and Recurrent Venous Thromboembolism after Renal Transplantation. THALASSEMIA REPORTS, 12(3), 85-89 [10.3390/thalassrep12030013].
A Patient with Sickle Cell Disease and Recurrent Venous Thromboembolism after Renal Transplantation
Di Maggio, RosarioPrimo
;Giuliano, Alessandra;Calvaruso, Giuseppina;Raso, Simona;Carroccio, AntonioCo-ultimo
;
2022-01-01
Abstract
Venous thromboembolism (VTE) is a life-threatening complication, specially in case of recurrence. The appropriate duration of anticoagulant treatment following the first event is crucial. Risk factors that increase the risk of recurrence of VTE are many, and include medications, kidney disease, renal transplantation (RT), and a diagnosis of sickle cell disease (SCD). There are currently no guidelines that define the duration of anticoagulant therapy after the first event in a patient with RT. We report a case of recurring episodes of VTE after RT in a SCD patient. Our case suggests that the use of a long-term anticoagulant treatment may be recommended in patients with SCD and RT after the first event of VTE.File | Dimensione | Formato | |
---|---|---|---|
Thalass Rep 2022sickle cell.pdf
accesso aperto
Tipologia:
Versione Editoriale
Dimensione
2.46 MB
Formato
Adobe PDF
|
2.46 MB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.